ArticleInternational journal of molecular sciences2020
Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Nanoparticle-based drug delivery systems in urologic oncology: From targeted therapy to precision theranostics.Materials today. Bio · 2025Review
- pH-triggered liposomal strategy for cisplatin in lung cancer therapy.Scientific reports · 2025Article
- Comparative In Vitro Evaluation of Buccal Films, Microcapsules, and Liposomal Systems for Naringin andPharmaceutics · 2025Article
- Progress on liposome delivery systems in the treatment of bladder cancer.RSC advances · 2025Review
- Innovative PEGylated chitosan nanocarriers for co-delivery of doxorubicin and CpG in breast cancer therapy: Preparation, characterization, and immunotherapeutic potential.Medical oncology (Northwood, London, England) · 2025Article
- Synthesis, radiolabeling, and biodistribution of 99 m-technetium-labeled zif-8 nanoparticles for targeted imaging applications.3 Biotech · 2024Article
- Impact of PEGylated liposomes on cytotoxicity of tamoxifen and piperine on MCF-7 human breast carcinoma cells.Journal of drug delivery science and technology · 2024Article
- Liposomal Formulations of Metallodrugs for Cancer Therapy.International journal of molecular sciences · 2024Review
- Cisplatin-based miRNA delivery strategy inspired by the circCPNE1/miR-330-3p pathway for oral squamous cell carcinoma.Acta pharmaceutica Sinica. B · 2024Article
- Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges.Life (Basel, Switzerland) · 2024Review
- Enhancing the efficacy of letrozole-loaded PEGylated nanoliposomes against breast cancer cells:Heliyon · 2024Article
- Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.Current pharmaceutical design · 2024Review
- Development of Responsive Nanoparticles for Cancer Therapy.International journal of molecular sciences · 2023Article
- Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery.Nanoscale advances · 2023Review
- Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma.Pharmaceutics · 2022Article
- A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics.Pharmaceutics · 2022Article
- Microemulsion Delivery System Improves Cellular Uptake of Genipin and Its Protective Effect against Aβ1-42-Induced PC12 Cell Cytotoxicity.Pharmaceutics · 2022Article
- pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer.ACS applied bio materials · 2022Article
- Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: anEXCLI journal · 2022Article
- Development and evaluation of luteolin loaded pegylated bilosome: optimization,Drug delivery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder cancer (BC). Cispt was loaded into liposomes using reverse-phase evaporation method, and the formulations were characterized using dynamic light scattering, scanning electron microscopy, dialysis membrane, and Fourier-transform infrared spectroscopy (FTIR) methods. The results showed that the particles were formed in spherical monodispersed shapes with a nanoscale size (221-274 nm) and controlled drug release profile. The cytotoxicity effects of LCispt and PLCispt were assessed in an in vitro environment, and the results demonstrated that PLCispt caused a 2.4- and 1.9-fold increase in the cytotoxicity effects of Cispt after 24 and 48 h, respectively. The therapeutic and toxicity effects of the formulations were also assessed on BC-bearing rats. The results showed that PLCispt caused a 4.8-fold increase in the drug efficacy (tumor volume of 11 ± 0.5 and 2.3 ± 0.1 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.